Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled SAN FRANCISCO and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., ...

Dupixent continues to be a significant growth driver for Regeneron ... The program is advancing rapidly and targets a large market opportunity in thrombosis treatment. While the mechanism isn't fully ...

Dupixent continues to be a significant growth ... targets a large market opportunity in thrombosis treatment. While the mechanism isn't fully de-risked and requires large, expensive Phase III ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex landscape of challenges and opportunities in recent months. According to ...

Sales of Dupixent grew by an impressive 29% year-over ... targeting anticoagulation with a differentiated mechanism of action. 2. Fianlimab: An antibody targeting LAG-3 for melanoma treatment ...

In this Review, we summarise common mechanisms driving acute and long-term side-effects and discuss monitoring strategies for radiotherapy survivors. We explore ways to mitigate toxic effects through ...

"These findings illuminate a critical mechanism that connects local synaptic activity to the broader gene expression changes necessary for learning and memory," said Mark Dell'Acqua, professor of ...

At the centre of the dermatology market and within the interleukin inhibitor drug class, Sanofi takes a leading position with its blockbuster drug Dupixent (dupilumab ... opportunities for therapies ...

The international team describes their results and the underlying molecular mechanism in Cell Metabolism. Ergothioneine is a natural compound found in certain fungi such as oyster or shiitake ...

The success of Dupixent has demonstrated the viability ... With its innovative mechanism of action and established success in asthma, Fasenra could address critical safety and efficacy gaps ...